After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...
Not all patients will want to take triplet therapy, but those with high-volume prostate cancer who are chemotherapy eligible are usually a good fit, explained Neal D. Shore, MD, FACS. For patients ...
In a recent ranking of each NFL team’s triplets, the New York Giants came in at No. 29. NFL.com’s Gennero Felice took each team’s quarterback, top running back, and top pass catcher and ...
1 The triplet also resulted in a 47% reduction in the risk of disease progression or death vs the doublet. At a median follow-up of 11.1 months (95% CI, 8.6-14.2) for the triplet and 8.8 months (95% ...